## 참고문헌

1.  Guidance. NIfHaCE. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. London: Royal College of Physicians (UK). 2011.
2.  Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996;77(1):37–42.
3.  Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142.
4.  British Thoracic Society Standards of Care C, Joint Tuberculosis C, Milburn H, Ashman N, Davies P, Doffman S, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–70.
5.  Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron. 1993;64(2):169–81.
6.  Strauss I, Erhardt F. Ethambutol absorption, excretion and dosage in patients with renal tuberculosis. Chemotherapy. 1970;15(3):148–57.
7.  Queensland Government. Treatment of tuberculosis in renal disease–Guidelines, Version 4.0. the State of Queensland (Queensland Health). July 2021.
8.  World Helath Organization. WHO operational handbook on tuberculosis. Module 4: Treatment; Drug–susceptible tuberculosis treatment 2022 update Web Annexes. 2022.

<PAGE>163